333 related articles for article (PubMed ID: 26041296)
1. Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening.
Rathbun JY; Droniou ME; Damoiseaux R; Haworth KG; Henley JE; Exline CM; Choe H; Cannon PM
J Virol; 2015 Aug; 89(16):8428-43. PubMed ID: 26041296
[TBL] [Abstract][Full Text] [Related]
2. Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.
Torriani G; Trofimenko E; Mayor J; Fedeli C; Moreno H; Michel S; Heulot M; Chevalier N; Zimmer G; Shrestha N; Plattet P; Engler O; Rothenberger S; Widmann C; Kunz S
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626681
[TBL] [Abstract][Full Text] [Related]
3. Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of Arenavirus Multiplication.
Ngo N; Henthorn KS; Cisneros MI; Cubitt B; Iwasaki M; de la Torre JC; Lama J
J Virol; 2015 Nov; 89(21):10924-33. PubMed ID: 26292327
[TBL] [Abstract][Full Text] [Related]
4. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses.
Lee AM; Rojek JM; Spiropoulou CF; Gundersen AT; Jin W; Shaginian A; York J; Nunberg JH; Boger DL; Oldstone MB; Kunz S
J Biol Chem; 2008 Jul; 283(27):18734-42. PubMed ID: 18474596
[TBL] [Abstract][Full Text] [Related]
5. Reverse Genetics Approaches to Control Arenavirus.
Martínez-Sobrido L; Cheng BY; de la Torre JC
Methods Mol Biol; 2016; 1403():313-51. PubMed ID: 27076139
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening for negative-stranded hemorrhagic fever viruses using reverse genetics.
Wendt L; Bostedt L; Hoenen T; Groseth A
Antiviral Res; 2019 Oct; 170():104569. PubMed ID: 31356830
[TBL] [Abstract][Full Text] [Related]
7. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092
[No Abstract] [Full Text] [Related]
8. A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus.
Thomas CJ; Casquilho-Gray HE; York J; DeCamp DL; Dai D; Petrilli EB; Boger DL; Slayden RA; Amberg SM; Sprang SR; Nunberg JH
J Biol Chem; 2011 Feb; 286(8):6192-200. PubMed ID: 21159779
[TBL] [Abstract][Full Text] [Related]
9. Tangeretin, an extract from Citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever.
Tang K; He S; Zhang X; Guo J; Chen Q; Yan F; Banadyga L; Zhu W; Qiu X; Guo Y
Antiviral Res; 2018 Dec; 160():87-93. PubMed ID: 30339847
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches in anti-arenaviral drug development.
Lee AM; Pasquato A; Kunz S
Virology; 2011 Mar; 411(2):163-9. PubMed ID: 21183197
[TBL] [Abstract][Full Text] [Related]
11. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform.
Welch SR; Spengler JR; Genzer SC; Chatterjee P; Flint M; Bergeron É; Montgomery JM; Nichol ST; Albariño CG; Spiropoulou CF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34203149
[TBL] [Abstract][Full Text] [Related]
12. Novel drug discovery approaches for treating arenavirus infections.
Pasquato A; Kunz S
Expert Opin Drug Discov; 2016; 11(4):383-93. PubMed ID: 26882218
[TBL] [Abstract][Full Text] [Related]
13. Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses.
Dunham EC; Leske A; Shifflett K; Watt A; Feldmann H; Hoenen T; Groseth A
Antiviral Res; 2018 Sep; 157():140-150. PubMed ID: 30031760
[TBL] [Abstract][Full Text] [Related]
14. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
Martinez-Sobrido L; de la Torre JC
Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
[TBL] [Abstract][Full Text] [Related]
15. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.
Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor.
Ortiz-Riaño E; Ngo N; Devito S; Eggink D; Munger J; Shaw ML; de la Torre JC; Martínez-Sobrido L
J Virol; 2014 Jan; 88(2):878-89. PubMed ID: 24198417
[TBL] [Abstract][Full Text] [Related]
17. Reverse genetics approaches to combat pathogenic arenaviruses.
de la Torre JC
Antiviral Res; 2008 Dec; 80(3):239-50. PubMed ID: 18782590
[TBL] [Abstract][Full Text] [Related]
18. Current drug discovery strategies against arenavirus infections.
Pasquato A; Burri DJ; Kunz S
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1297-309. PubMed ID: 23241187
[TBL] [Abstract][Full Text] [Related]
19. Development of Reverse Genetics for the Prototype New World Mammarenavirus Tacaribe Virus.
Ye C; de la Torre JC; Martínez-Sobrido L
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669332
[TBL] [Abstract][Full Text] [Related]
20. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.
Olschläger S; Flatz L
PLoS Pathog; 2013; 9(4):e1003212. PubMed ID: 23592977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
